Validation of an improved insect bite hypersensitivity severity score for allergic equine insect bite hypersensitivity in horses.

Overview

• This research developed and validated a new clinical scoring system, called the equine IBH severity score (EqIS), for assessing allergic insect bite hypersensitivity in horses.
• The study demonstrated that EqIS is a reliable, reproducible, and objective tool useful for standardized disease monitoring and treatment evaluation in the field.

Background and Objective

• Insect bite hypersensitivity (IBH) is the most prevalent allergic skin disease affecting horses, caused by allergic reactions to insect bites.
• Existing scoring systems to assess the severity of IBH lack thorough validation and standardization, which hinders consistent disease monitoring and comparison of treatment outcomes.
• The study’s primary goal was to develop and validate a sensitive, standardized, and reproducible scoring system specifically for IBH in horses to improve clinical evaluation.

Methods

• The study was prospective and conducted under field conditions in Switzerland, involving 44 privately-owned horses with clinically diagnosed IBH.
• The new tool, termed equine IBH severity score (EqIS), combines two components:
  • Lesion severity score: measures the intensity of skin lesions caused by IBH.
  • Area score: measures the extent or percentage of the affected skin area.
• These two measures were combined using a multiplicative algorithm to generate the EqIS.
• Six trained evaluators independently assessed the horses to test the scoring system’s reliability.
• The main measured outcomes:
  • Intraobserver reliability – consistency of the same evaluator’s scores across multiple assessments.
  • Interobserver reliability – agreement among different evaluators.
• Statistical tools:
  • Intraclass correlation coefficients (ICC) were used to quantify reliability of the lesion severity score and EqIS.
  • Pearson correlation assessed the agreement of the area score across evaluators.
  • Correlations between owner-reported visual analog scale (VAS) scores and EqIS were examined to check consistency with owner perspectives.
  • A simplified version of EqIS designed for routine field use was also compared to the fully validated EqIS to assess practicality.

Results

• Intraobserver reliability was excellent:
  • ICC = 0.995 for lesion severity score.
  • ICC = 0.989 for EqIS overall.
• Interobserver reliability was also very high:
  • ICC = 0.98 for both lesion severity score and EqIS.
• Area score showed strong agreement between evaluators:
  • Pearson correlation coefficients ranged from 0.86 to 0.94.
• Owner-reported VAS scores had a moderate correlation with EqIS (rho = 0.49-0.51), indicating decent but not perfect agreement between clinical evaluation and owner perception.
• Owner VAS scores correlated strongly with each other (rho = 0.88), showing consistency across different owners’ subjective assessments.
• The simplified EqIS for quick field use correlated strongly with the full validated score (R² = 0.86), suggesting it can be used as a practical alternative without major loss of accuracy.

Conclusions and Implications

• The EqIS is the first extensively validated, IBH-specific scoring system with demonstrated excellent reproducibility across multiple evaluators.
• Its multiplicative integration of lesion severity and affected area provides an objective and standardized method for assessing disease severity in horses with IBH.
• The tool allows for consistent disease monitoring and evaluation of therapeutic interventions in both research and clinical practice.
• The simplified version of EqIS offers veterinarians and owners a convenient option for routine assessment under field conditions.
• Overall, the study addresses a significant gap in equine dermatology by delivering a rigorously tested method to enhance clinical management of IBH.